Burns Levinson

The Path Forward After COVID-19 for Life Science Companies

July 14, 2020



amazing clients

Josef B. Volman

Partner | Co-Chair, Business Law

jvolman@burnslev.com
Boston, MA
D: 617.345.3895

Practices

Securities & Capital Markets
Innovation Program
Business, Finance & Transactions
Venture Capital & Emerging Companies
Middle-Market M&A and Private Equity
Life Sciences
Sports

Burns Levinson



Burns Levinson

Zoe was always late to meetings, but her dramatic entrances were worth waiting for.

©10CharlesFincher07.05 Scribble-in-Law.com

Burns Levinson

VC Market Overview (Mid-Year Comparison 2019 vs. 2020), as of June 17, 2020

From: Pandemic's VC deal toll: Midyear perspective, Pitchbook, July 29,2020

- Deal Flow Has Dropped. 4,675 funding rounds this year vs. 6,357 in last year's first half.
- VC Investment is Down. Investors bet $63.2 billion on VC-backed deals, down from $72.2 billion in the last year's first half.
- Investors Are Holding Onto Seed Capital . Deals plunged 45% to 803 vs. 1,447 deals done in the first half of 2019; Invested capital down to $2.2 billion from $3.3 billion.
- Mega-Rounds Maintained. Deals of $100 million or more are a bit behind last year's first-half tally, but the rough $29 billion sum of mega-fundraising rounds puts this category on track to surpass last year's $55 billion, the second-biggest haul on record